1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

A Competitive Analysis of the Global Breast Cancer Therapeutics Market : A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

  • March 2015
  • 68 pages
  • ID: 2779417
  • Format: PDF
  • By Frost & Sullivan

Summary

Table of Contents

Executive Summary

•The global breast cancer therapeutics market is divided into x segments: hormonal therapy, targeted therapy, chemotherapy, and other therapy (for example, novel drugs in development).
•About x hormonal therapies are available to treat breast cancer. The most common ones are aromatase inhibitors and selective oestrogen receptor modulators (SERMs).
•Only x approved targeted treatments are available in the U.S. market, namely, Herceptin (Roche) and Tykerb (GSK). 2 more drugs, Kadcyla (Roche) and Perjeta (Roche), were approved in 2013. At present, Roche dominates the global breast cancer therapeutics market.
•Although there are approximately x drugs indicated for the treatment of breast cancer, there remains a large unmet need to treat patients. As a result, the breast cancer pharmaceutical pipeline is strong, with about x drugs in development.
•Chemotherapy remains the most important class of drugs for breast cancer treatment; however, the trend of using targeted drugs is on the rise.
•Combination treatment is a focus for companies with breast cancer treatment in development; however, drugs that held potential in Phase 2 trials failed to make an impact in Phase 3, forcing companies to re-design trials or stop the research programme.
•Between 2015 and 2017, the key drugs to watch out for will be ABT-888 (AbbVie), NeuVax (Galena Biopharma), Palbociclib (Pfizer), NKTR-102 (Nektar), Nexavar (Bayer/Onyx), and CT-P6 (Celltrion).
•Palbocilib (Pfizer), LY2835219 (Eli Lilly), and LEE011(Novartis) are the most exciting drugs to look out for as they represent the cyclin-dependent kinases (CDK) unique class of drug inhibitors, a first of a kind from a breast cancer therapeutics perspective.
•Palbocilib is a CDK inhibitor oral drug that has been approved for filing and granted priority review by the U.S. Food and Drug Administration (FDA). If approved, this treatment will benefit patients as a first-line therapy (in combination with letrozole).
•LY2835219 (Eli Lilly) and LEE011 (Novartis) are the other key CDK inhibitors expected to compete with Palbocilib. Although no preliminary data is available in terms of Phase 3 trials, at present, they are anticipated with positive enthusiasm from their developers.
•In 2014, market size was estimated at $ x billion; the market is expected to witness a compound annual growth rate (CAGR) of x % over the next x years.

Physician Guidelines to Breast Cancer Therapy—Her 2 Positive

•Herceptin therapy, along with chemotherapy combination, such as Xeloda and Tykerb, represents the standard treatment regime for Her 2-positive breast cancer.
•This standard treatment is also being administered subcutaneously to reduce run time. Most breast cancer patients benefit from this therapy, demonstrating an affirmative response to Her 2 positive.
•New versions, such as Kadcyla and Perjeta, leverage Roche’s proprietary technology.

Physician Guidelines to Breast Cancer Therapy—ER or PR Positive

•Hormone-positive patients represent the next largest market and are usually treated with Faslodex, along with chemotherapeutic agents, such as anthracyclines or taxanes.
• Exemestane is usually prescribed after the failure of Tamoxifen. It also serves as a third-line therapy option for advanced breast cancer patients.

Physician Guidelines to Breast Cancer Therapy— Triple-negative Breast Cancer

•Ideally, anthracyclin or taxane is administered to patients with triple-negative breast cancer as they do not respond to either hormone therapy or Her 2-positive-targeted therapeutics.
•At present, new and promising therapeutic targets, such as CDKs, poly-adenosine ribose phosphates, and epidermal growth factor receptors are being evaluated to develop drugs to fulfil this unmet need.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Bone Metastasis - Pipeline Review, H2 2019

Bone Metastasis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Bone Metastasis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2019, provides an overview of the Bone Metastasis ...

Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019

Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019SummaryDual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein ...

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020SummaryGranulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on